The composition of our intestinal microbiota, may be a measure of our overall health. The presence of an imbalance in the microbial gut community is...
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
Screening tools for the evaluation of a drug’s ability to cross various biological membrane systems in a microplate format.
PAMPA
Caco-2
Figure 7. Example of Caco-2 Assay results. Assessment of the permeability of either Metoprolol (highly Permeable) or Quinidine (PgP substrate). A cell monolayer grown on a filtered-well is used to evaluate test compound movement between the insert (apical compartment -A) and the plate well (basal compartment -B). Passive transport through the layer is determine by A-B flux, whereas active transporter will introduce a B-A distribution of compounds between the two compartments.
Metabolism
In vitro drug metabolism studies, are a screening mechanism to characterize drug metabolites, elucidate their pathways, to help with further in vivo testing.
Hepatic Fractions (S9/Microsomes)
Hepatocyte
CYP Phenotyping
CYP Inhibition
Figure 5. Observes relationship between inhibitor
(Ketoconazole) and the substrate (Midazolam).
Figure 6. Inhibition Profile for CYP3A4
Protein Binding Analyses
Protein binding assays assesses the degree to which drugs attaches to proteins within the plasma/tissue. A drug’s efficacy may be affected by the degree to which it binds. TD2 has validated this assay using the Rapid Equilibrium Device and analysis done by LC-MS.
Plasma
Microsomal
Tumor/Tissue
Figure 3. The process of protein binding assessment with rapid equilibrium dialysis.
Figure 4. Protein binding analysis by equilibrium dialysis of plasma
across mutiple different speacies (mouse, rat, dog, monkely, human)
following exposure to multiple compounds.